SITGEC would like to congratulate Fondazione Telethon and HSR-TIGET on the milestone achievement of the FDA approval of WAS ex vivo gene therapy. Please see below their statement: We are honoured to share a moment of profound significance for us, for patients, families, and the scientific community.    The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for  Waskyra , the  first gene therapy for the treatment of Wiskott-Aldrich syn

SITGEC's first standalone meeting took place in June, following on from the success of their inaugural conference in October 2024, which was held in collaboration with ESGCT. The 'Thematic Day on Broadening and Securing access to ATMPs' took place on 6th June at Bambino Gesù Children's Hospital in Rome.

We would like to bring to your attention the upcoming  EMBO Workshop  titled “CRISPR-Cas: from biology to therapeutic applications”,...

Fondazione Telethon launches a new training initiative for early-career scientists at its flagship Institutes Fondazione Telethon is a...

The San Raffaele Telethon Institute for Gene Therapy (SR-TIGET - www.sr-tiget.it ) is seeking tenure- track GROUP LEADERS wishing to...

The 31st ESGCT Annual Congress took place in collaboration with SITGEC on 22-25 October 2024 at La Nuvola in Rome. Fondazione Telethon...

Read the press release here for full details.

See a summary of SITGEC's headline numbers from 2024.

More than 1000 school students attended an event organised by Fondazione Telethon at the ESGCT/SITGEC Congress. Watch the event video here.